Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685841 · ClinicalTrials.gov registry record · Phase 3
A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 717
- Enrollment target
NCT00685841 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 717 participants.
The verdict
NCT00685841, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 717 participants
- Enrollment target
Study Summary
A 12 week study to investigate the safety and effectiveness of arformoterol given twice daily compared to placebo in subjects with COPD.
Interventions
- DRUG Placebo
- DRUG Arformoterol tartrate inhalation solution
- DRUG Salmeterol MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 717 participants |
| Start Date | 2002-02 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685841
The ClinicalTrials.gov registry entry for NCT00685841 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 717 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00685841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685841 about?
NCT00685841 is a clinical study titled "A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". A 12 week study to investigate the safety and effectiveness of arformoterol given twice daily compared to placebo in subjects with COPD.
What is the current status of trial NCT00685841?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 717 participants. The study started on 2002-02. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00685841?
The interventions under investigation include: Placebo (DRUG), Arformoterol tartrate inhalation solution (DRUG), Salmeterol MDI (DRUG).
Who is sponsoring clinical trial NCT00685841?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.